Needham & Company LLC Reiterates "Buy" Rating for Collegium Pharmaceutical (NASDAQ:COLL)

Needham & Company LLC reaffirmed their buy rating on shares of Collegium Pharmaceutical (NASDAQ:COLL - Free Report) in a research report sent to investors on Wednesday,Benzinga reports. They currently have a $46.00 price target on the specialty pharmaceutical company's stock.

Several other analysts have also recently commented on COLL. Piper Sandler decreased their price objective on shares of Collegium Pharmaceutical from $37.00 to $36.00 and set a "neutral" rating for the company in a research note on Tuesday, February 4th. HC Wainwright reaffirmed a "buy" rating and set a $50.00 price target on shares of Collegium Pharmaceutical in a research report on Monday, March 24th. One equities research analyst has rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Buy" and an average price target of $43.60.

Collegium Pharmaceutical Stock Performance

Shares of NASDAQ:COLL traded up $0.26 on Wednesday, hitting $26.56. 127,407 shares of the company were exchanged, compared to its average volume of 442,127. The firm has a market capitalization of $853.43 million, a P/E ratio of 11.45 and a beta of 0.76. The company has a current ratio of 0.97, a quick ratio of 0.88 and a debt-to-equity ratio of 3.43. Collegium Pharmaceutical has a 1-year low of $23.23 and a 1-year high of $42.29. The stock's 50 day moving average price is $29.14 and its 200 day moving average price is $31.55.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last issued its quarterly earnings results on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 EPS for the quarter, topping analysts' consensus estimates of $1.54 by $0.09. The company had revenue of $181.95 million during the quarter, compared to analysts' expectations of $179.68 million. Collegium Pharmaceutical had a return on equity of 104.67% and a net margin of 14.78%. Sell-side analysts predict that Collegium Pharmaceutical will post 5.62 EPS for the current year.

Insider Buying and Selling

In other Collegium Pharmaceutical news, EVP Shirley R. Kuhlmann sold 40,000 shares of the company's stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $28.08, for a total value of $1,123,200.00. Following the transaction, the executive vice president now owns 154,204 shares of the company's stock, valued at $4,330,048.32. This represents a 20.60 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CFO Colleen Tupper sold 1,949 shares of Collegium Pharmaceutical stock in a transaction dated Thursday, March 6th. The shares were sold at an average price of $30.00, for a total transaction of $58,470.00. Following the sale, the chief financial officer now owns 177,195 shares of the company's stock, valued at approximately $5,315,850. This represents a 1.09 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 81,693 shares of company stock worth $2,334,994. Insiders own 3.98% of the company's stock.

Institutional Investors Weigh In On Collegium Pharmaceutical

Several large investors have recently added to or reduced their stakes in the business. New Age Alpha Advisors LLC purchased a new stake in shares of Collegium Pharmaceutical during the fourth quarter worth $40,000. TD Private Client Wealth LLC grew its stake in Collegium Pharmaceutical by 39.5% during the 3rd quarter. TD Private Client Wealth LLC now owns 1,707 shares of the specialty pharmaceutical company's stock worth $66,000 after purchasing an additional 483 shares in the last quarter. KBC Group NV increased its holdings in Collegium Pharmaceutical by 72.5% during the 4th quarter. KBC Group NV now owns 2,336 shares of the specialty pharmaceutical company's stock worth $67,000 after purchasing an additional 982 shares during the period. Virtus Fund Advisers LLC raised its position in Collegium Pharmaceutical by 30.5% in the 4th quarter. Virtus Fund Advisers LLC now owns 2,419 shares of the specialty pharmaceutical company's stock valued at $69,000 after purchasing an additional 565 shares in the last quarter. Finally, Nisa Investment Advisors LLC boosted its stake in shares of Collegium Pharmaceutical by 14.5% in the 4th quarter. Nisa Investment Advisors LLC now owns 2,493 shares of the specialty pharmaceutical company's stock valued at $71,000 after buying an additional 316 shares during the period.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.